Acute gastrointestinal toxicity after robotic stereotactic ablative radiotherapy for treatment of metastatic gynecological malignancies

Author:

Mislmani Mazen1,Frasure Heidi2,Suppiah Somu3,Fabien Jeffrey1,Lo Simon S4,Debernardo Robert5,Kunos Charles A1

Affiliation:

1. Department of Radiation Oncology, University Hospitals Seidman Cancer Center & Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

2. Department of Obstetrics & Gynecology, University Hospitals Case Medical Center & Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

3. Southern Illinois University School of Medicine, Springfield, IL 62794, USA

4. Department of Radiation Oncology, University Hospitals Seidman Cancer Center & Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

5. Department of Obstetrics & Gynecology, Cleveland Clinic Foundation, Cleveland, OH 44106, USA

Abstract

ABSTRACT Aims: The aim of this study was to assess acute and subacacute gastrointestinal toxicity after fractionated stereotactic ablative radiotherapy (SABR) in women having recurrent gynecological cancers in the upper abdomen. Materials & methods: In total, 34 women underwent upper abdominal SABR (24 Gy/three divided 8 Gy consecutive daily doses) using a robotic Cyberknife® (Accuray, CA, USA) platform. Volumes of the duodenum receiving 10% increments of the prescription dose were associated to post-therapy gastrointestinal toxicities using binary logistic regression analyses. Results: Median clinical follow-up was 10 months. In total, 14 (41%) of the 34 women manifested grade 2 or higher post-therapy gastrointestinal adverse events. The duodenal volume, receiving 80% of a 24-Gy dose, was significantly associated with gastrointestinal toxicity (p = 0.03). However, in a multivariate analysis, only patient age at SABR adjusted the odds of experiencing gastrointestinal toxicity (p = 0.02). Conclusion: The duodenal volume receiving 80% of 24 Gy dose may be associated with gastrointestinal toxicity from upper abdominal SABR.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3